Vitamin D and type 2 diabetes mellitus: mechanisms, clinical evidence, and future perspectives

Abstract Background Recently, the significance of Vitamin D has been acknowledged for its role in bone health, as well as its essential function in regulating glucose metabolism, improving insulin response, and reducing inflammation—all important variables in the progression of type 2 diabetes (T2DM). A hypothesis suggests an inverse relationship between blood levels of 25-hydroxyvitamin D and the risk of type 2 diabetes; however, the results of clinical trials have not always been consistent. Objective This review aims to analyze the available clinical and epidemiological evidence on the connection between T2DM risk and vitamin D levels, focusing on potential biological explanations, observed trends, and outcomes of clinical interventions. Methods Randomized controlled clinical trials, long-term observational studies, and mechanistic research published in peer-reviewed scientific journals were reviewed, with a focus on relevant biological pathways, clinical outcomes, and knowledge gaps in the current literature. Results Population studies indicate that elevated serum 25(OH)D levels are associated with a 30% to 40% lower risk of diabetes. Biological data support this association, as vitamin D enhances insulin secretion from pancreatic beta cells, enhances the sensitivity of peripheral tissues to insulin, and reduces inflammation. However, clinical trial results have shown limited and inconsistent improvements in blood sugar regulation parameters, with greater benefit observed in individuals who were initially vitamin D deficient. Conclusion Adequate Vitamin D levels may be beneficial in improving glycemic control, especially in at-risk groups or those with vitamin D deficiency. Future studies require a rigorous design that considers genetic, environmental, and lifestyle factors. Vitamin D may support the management of T2DM, but it cannot be established as a standalone treatment.